| abstract |
Compounds of formula (I) are described: wherein R1, R2, R3, R4, R5 and p are as described in the specification and pharmaceutically acceptable and hydrolysable salts in vivo. Also described are processes for their preparation and use as medicaments, particularly medicaments to produce an inhibitory effect of the cell site (anti-cell proliferation) in a client blood animal, such as man. |